Clinical trial
Aliskiren in Combination With Losartan Compared to Losartan on the Regression of…
NCT00219141 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00219141 |
|---|---|
| Title | Aliskiren in Combination With Losartan Compared to Losartan on the Regression of Left Ventricular Hypertrophy in Overweight Patients With Essential Hypertension |
| Official title | A 36-week, Randomized, Double-blind, Multi-center, Parallel Group Study Comparing the Efficacy and Safety of Aliskiren in Combination With Losartan Compared to Losartan on the Regression of Left Ventricular Hypertrophy in Overweight Patients With Essential Hypertension |
| Acronym | ALLAY |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Hypertension, Left Ventricular Hypertrophy, Overweight |
| Intervention type | Drug |
| Interventions | Aliskiren 150/300 mg, Losartan 50/100 mg, Aliskiren placebo, Losartan 50/100 mg placebo |
| Enrollment | 460 |
| Start date | Oct 1, 2005 |
| Primary completion | Nov 1, 2007 |
| Completion | Nov 1, 2007 |
| First posted | Sep 22, 2005 |
| Last update posted | May 26, 2011 |
| Countries | Argentina, Colombia, Finland, Germany, Italy, Russia, Spain, Sweden, United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: